SCHEMBL30591069

SCHEMBL30591069

COc1cc(CCN)c(OC)c(Br)c1C

nearest known ligand 0.56

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 7/20 0.56
TAAR1 Q96RJ0 6/20 0.56
HTR2C P28335 4/20 0.56
CYP1A2 P05177 1/20 0.54
HTR2B P41595 2/20 0.47
ADRA1A P35348 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29633122 0.86 CYP1A2 (0.61) HTR2ATAAR1HTR2CCYP1A2HTR2B
SCHEMBL14655685 0.86 CYP1A2 (0.61) HTR2ATAAR1HTR2CCYP1A2HTR2B
SCHEMBL23753586 0.84 CYP1A2 (0.59) HTR2ATAAR1HTR2CCYP1A2HTR2B
Hydrochloric Acid SCHEMBL6030030 0.84 CYP1A2 (0.59) HTR2ATAAR1HTR2CCYP1A2HTR2B
SCHEMBL9952484 0.83 CYP1A2 (0.46) HTR2ATAAR1HTR2CCYP1A2HTR2B
SCHEMBL23753584 0.83 TAAR1 (0.59) HTR2ATAAR1HTR2CCYP1A2HTR2B
SCHEMBL9952029 0.82 TAAR1 (0.46) HTR2ATAAR1HTR2CCYP1A2HTR2B
Hydrochloric Acid SCHEMBL9952054 0.81 TAAR1 (0.45) HTR2ATAAR1HTR2CCYP1A2HTR2B
SCHEMBL31284935 0.80 CYP1A2 (0.54) HTR2ATAAR1HTR2CCYP1A2HTR2B
SCHEMBL23360636 0.80 CYP1A2 (0.54) HTR2ATAAR1HTR2CCYP1A2HTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119173636-A RNA molecules 帝国理工学院创新有限公司 2024-12-20 CN claimed
EP-4486909-A2 RNA MOLECULE Imperial College Innovations Limited (GB) 2025-01-08 EP disclosed
CN-119173636-A RNA molecules 帝国理工学院创新有限公司 2024-12-20 CN disclosed
US-12024707-B2 Methods and compositions for modulating lncRNAs and methods of treatment based on lncRNA expression WASHINGTON UNIVERSITY (US) 2024-07-02 US disclosed
US-20240165267-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF ARES CAPITAL CORPORATION, AS AGENT 2024-05-23 US disclosed
WO-2023166314-A2 RNA MOLECULE IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2023-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240165267-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 HTR2A 3045/4885TAAR1 3484/4885HTR2C 4194/4885
US-12024707-B2 Methods and compositions for modulating lncRNAs and methods of treatment based on lncRNA expression HNRNPH3, NSUN2, HNRNPAB HTR2A 1764/4885TAAR1 3932/4885HTR2C 2747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.